Volume 5, Issue 3 (Multidisciplinary Cancer Investigation – July 2021)                   Multidiscip Cancer Investig 2021, 5(3): 1-12 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Yan J, Li T, Wang Y, Zhu H, Liu R, Lei Z et al . The Efficacy and Safety of Iodine-125 Implantation Combined with Gemcitabine in the Treatment of Advanced Pan- creatic Cancer: A Systematic Review and Meta-analysis. Multidiscip Cancer Investig. 2021; 5 (3) :1-12
URL: http://mcijournal.com/article-1-309-en.html
Abstract:   (599 Views)
Introduction: A systematic review and meta-analysis was conducted to assess the efficacy and safety of iodine-125 implantation combined with gemcitabine in the treatment of advanced pancreatic cancer.
Methods:  PubMed,  Chinese  National  Knowledge  Infrastructure  database  (CNKI), Cochrane Library, Embase, and Wanfang database through Oct 2020 were searched
for randomized controlled trials (RCTs) and retrospective studies assessing the efficacy
and  safety  of  iodine-125  implantation  combined  with  gemcitabine  in  the  treatment  of advanced  pancreatic  cancer.  The  main  outcome  measures  included  the  overall  remission [complete  response  (CR)+partial  response  (PR)]  rate,  overall  survival  (OS),  hypofunction of the liver, clinical benefit response (CBR) rate, survival rate, and adverse events.
Results:   Totally,   19   studies   involving   1496   patients   were   included   in   the   current systematic review and meta-analysis. The pooled results showed that efficacy and safety of  patients  treated  with  Iodine-125  combined  with  gemcitabine  were  superior  to  those undergoing  gemcitabine  alone:  overall  remission  (CR+PR)  rate  [odds  ratio  (OR)=3.10, 95% confidence interval (CI): 2.40, 4.00; P<0.00001], OS [hazard ratio (HR)=0.56, 95% CI: 0.47, 0.68; P<0.00001], hypofunction of liver (OR=1.08, 95% CI: 0.67, 1.74;
P=0.75), CBR rate (OR=3.85, 95% CI: 2.83, 5.22; P<0.00001), survival rate of six months (OR=3.44 95% CI: 1.83, 6.46) and survival rate of 12 months (OR=2.67, 95% CI: 1.68, 4.26). And there was no statistical association in adverse events between the groups.
Conclusions:   The   combination   of   iodine-125   seed   implantation   and   gemcitabine significantly prolonged the survival of patients with pancreatic cancer, compared with the gemcitabine alone, indicating a better prognosis.
Full-Text [PDF 1686 kb]   (352 Downloads)    
Type of Study: Review Article | Subject: treatment
Received: 2021/02/28 | Accepted: 2021/06/15 | ePublished: 2021/07/27

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb